Experts join MD Anderson to end a cancer -
The University of Texas MD Anderson Cancer Center is pleased to announce that one of the leading experts in the world research and breast cancer treatment, V. Craig Jordan, Ph.D., will join the institution's efforts to end cancer. Jordan is considered the "father of tamoxifen," the revolutionary therapeutic drug that has saved countless lives.
As a professor in Breast Medical Oncology and Molecular and Cellular Oncology Jordan will focus on the new biology of the cell estrogen-induced death in order to develop translation approaches to treatment and prevention cancer. He began working at MD Anderson in October.
"This is an exciting time and I am delighted that Dr. Jordan will contribute to the important translational research in breast cancer here at MD Anderson," said Ron DePinho, MD, president of MD Anderson. "His international reputation as a pioneer in translational research and his many achievements and accolades are well deserved. As we progress in our mission to end cancer in Texas, the nation and the world, it is of eminent scientists like Dr. Jordan who will play key roles in this promise. "
long and distinguished executive career positions Jordan included in some of the most prestigious biomedical institutions in the world. Currently he is scientific director of the Comprehensive Cancer Center at Lombardi at Georgetown University in Washington, DC, and Vincent T. Lombardi president of translational cancer research. He is also vice president of the Department of Oncology and professor of oncology and pharmacology at the Medical School of the University of Georgetown. In addition, he is a visiting professor of molecular medicine at the University of Leeds in England, and assistant professor of molecular pharmacology and biological chemistry at Northwestern University in Chicago.
"the election of Dr. Jordan as a member of the National Academy of Sciences in 09 is just one of many honors he received following his incredible contributions to our understanding of biology cancer, "said Ethan Dmitrovsky, MD, MD Anderson provost and executive vice president. "MD Anderson is known for bringing together the best minds in the common goal of ending cancer. Certainly, a scientist of the caliber of Dr. Jordan adds significantly to our global research programs. His arrival is due in large part to the efforts Debu Tripathy, MD and Vicente Valero, MD "
Dr. Tripathy is new president of MD Anderson breast medical oncology. He will begin his work at the institution in September.
In addition to his membership in the National Academy, the Jordan's achievements list, awards and achievements is long, with more than four dozen international awards. The list includes:
• The Price of St. Gallen Breast Cancer (2011)
• The Price Karnofsky David A. American Society of Clinical Oncology (08)
• The George Price and Christine Sosnovsky in Cancer Therapy (04)
• Charles F. Kettering Prize (03)
• American Cancer Society Medal of Honor (02)
• the Dorothy P. Landon Price translational research the American Association for Cancer Research (02)
• Bristol Myers Squibb award (01)
• Cameron Price of the University of Edinburgh (1993)
Jordan received six scholarships or honorary degrees from universities around the world, including an honorary fellowship of the Royal Society of Medicine. In 2010 he was elected president of the Royal Society Foundation Medicine in North America. Jordan was elected as a member of the Academy of Medical Sciences, the equivalent of the UK Institute of Medicine.
He has contributed to over 700 publications, 99 percent relating to cancer research. He published 11 books and more than 26,000 scientific citations. He is the author of the book "Tamoxifen, a pioneer in the medicine of breast cancer."
Jordan, who was born in New Braunfels, Texas and raised in England, has dual British and American nationality. In 02 he received the Order of the British Empire by Queen Elizabeth II for services to international research on breast cancer. He earned a PhD and D.Sc. University of Leeds in 01, received an honorary M.D. of his alma mater.
"I am proud to be joining MD Anderson Cancer Center," said Jordan. "It is indeed an honor to continue my work in this world-renowned cancer center where I look forward to working with my distinguished colleagues."
Jordan is credited with reinventing a failed contraceptive (known as ICI 46474) as a breast cancer treatment. The drug, which has existed since the 1960s, was originally created to block estrogen in the hope of preventing pregnancy. Jordan developed the adjuvant treatment strategy for long-term tamoxifen, and the description and decipher the properties of a new group of drugs called selective estrogen receptor modulators (SERMs). He was the first to discover the preventive capacities of both tamoxifen and raloxifene drug. The drugs have been approved by the FDA to reduce breast cancer incidence in women at high risk.
EmoticonEmoticon